Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients

  • After a Type C meeting with the FDA, Aptinyx Inc APTX has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD).
  • The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (Study 1) and 150 mg (Study 2).
  • Both the studies will have 300 patients each.
  • Study 1 will start in Q4 of 2021, while Study 2 will commence in Q1 of 2022.
  • Additionally, Aptinyx disclosed an updated statistical analysis for the recently concluded exploratory Phase 2 study in PTSD after detecting a statistical error made by its contract research organization.
  • “The revised analysis does not impact our conclusions from that study, our confidence in the efficacy and safety profile of NYX-783, or our next steps in its clinical development,” said Norbert Riedel, CEO of the company.
  • After updated statistical analysis, certain study calculations such as CAPS-5 Arousal & Reactivity score and CAPS-5 Negative Cognitions and Mood score for the 50 mg dose vs. placebo had higher p-values than previously reported.
  • But each remains below the significance threshold pre-specified in the statistical analysis plan, it added.
  • Price Action: APTX shares are down 10.60% at $3.12 in the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsPhase 2 TrialPTSD
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!